B
휴젤
145020KOSDAQ55.0 / 100
Reference Date: 2026-10-23
Financial Score30.5 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 21.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Hujeel develops and manufactures biopharmaceuticals based on Clostridium botulinum type A toxin, and directly handles sales after merging with its subsidiary, Hujel Pharma, in 2018. Its major subsidiary, Acros, focuses on HA filler development and production. Both botulinum toxin and HA fillers have broad applications in medical and cosmetic fields.
Number of Employees
629people
Average Salary
64.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
13.80Industry Average 15.005.0Point
In line with industry avg
PBR
2.30Industry Average 1.201.0Point
1.9x industry avg (risky)
ROE
16.14Industry Average 8.007.0Point
2.0x industry avg (excellent)
Debt Ratio
0.37Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20259.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.3% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲31.0% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 15.3% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (10%, downtrend)
Current 180,200Won52-week high 296,50052-week low 166,500
1-month return0.0Point
1m -21.48% (strong drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral기업설명회(IR)개최2026-09-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-30